cholesteryl butyrate
cholest-5-en-3b-ol butyrate
Identification
| Name | cholesteryl butyrate |
| IUPAC | [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] butanoate |
| CAS Number | 521-13-1 |
| EINECS | 208-304-7 |
| FDA UNII | 50QA4YCP7F |
| Molecular Formula | C31 H52 O2 |
| Molecular Weight | 456.75384000 |
| MDL Number | MFCD00021144 |
| Nikkaji Number | J60.879C |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Boiling Point | 518.00 °C. @ 760.00 mm Hg (est) |
| Flash Point | 508.00 °F. TCC ( 264.30 °C. ) (est) |
| logP (o/w) | 11.770 (est) |
| Soluble in | water, 9.339e-007 mg/L @ 25 °C (est) |
Cosmetic Information
| CosIng | cosmetic data |
| Cosmetic Uses | skin conditioning |
No sensory data available
Safety Information
| Preferred SDS | View |
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | cosmetic ingredient for skin conditioning |
| Recommendation for cholesteryl butyrate usage levels up to | not for fragrance use. |
| Recommendation for cholesteryl butyrate flavor usage levels up to | not for flavor use. |
Potential Uses
Natural Occurrence
Synonyms
butanoic acid, (3b)-cholest-5-en-3-yl ester
butyric acid cholesteryl ester
cholest-5-en-3b-ol butyrate
cholest-5-en-3beta-ol butyrate
5-
cholesten-3b-ol 3-butyrate
cholesterol butyrate
cholesteryl butanoate
cholesteryl N-butyrate
[(3S,8S,9S,10R,13R,14S,17R)-10,13-
dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] butanoate
3b-
hydroxy-5-cholestene 3-butyrate
PubMed:
Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.
PubMed:
Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells.
PubMed:
Influence of supercritical CO(2) pressurization on the phase behavior of mixed cholesteryl esters.
PubMed:
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model.
PubMed:
Application of comprehensive two-dimensional gas chromatography to sterols analysis.
PubMed:
Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug.
PubMed:
Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?
PubMed:
Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells.
PubMed:
Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
PubMed:
Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells.
PubMed:
In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction.
PubMed:
The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation.
PubMed:
Fatty acid steryl, stanyl, and steroid esters by esterification and transesterification in vacuo using Candida rugosa lipase as catalyst.
PubMed:
Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery.
PubMed:
Cholesterol quantitation by GLC: artifactual formation of short-chain steryl esters.
PubMed:
Use of the minimal function for partial structure development in direct methods.
PubMed:
Crystal structure of cholesteryl butanoate at 123 K.
PubMed:
Simultaneous estimation of urinary steroids by semi-automated gas chromatography. Investigation of neo-natal infants and children with abnormal steroid synthesis.